ALS MND News Digest

Neuraltus Pharmaceuticals Announces Phase 2 Clinical Results for NP001 in ... NEWS.GNOM.ES Neuraltus Pharmaceuticals Announces Phase 2 Clinical Results for NP001 in Patients with Amyotrophic Lateral Sclerosis (ALS). PALO ALTO, Calif., Oct. 30, 2012 /NEWS.GNOM.ES/ – Neuraltus Pharmaceuticals, a private biopharmaceutical company ... See all stories on this topic »

ALS Treatment Target Found With Help From Yeast Medical News Today With the help of baker's yeast, a tiny one-celled organism, scientists in the US say they have found a "chink in the armor" of the currently incurable disease Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease. They suggest their ... See all stories on this topic »